Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

Cell & Gene Therapy Insights 2020; 6(7), 947–953


Published: 18 August 2020
Stefan Scheding, Heather Main, Pontus Blomberg

Advanced therapy medicinal products (ATMPs) have the potential to transform medicine, with the promise to treat, manage and cure some of the most severe diseases. However, the development of ATMPs is complex and successful transition from preclinical research to the approved clinical product faces a number of hurdles regarding technical as well regulatory and societal challenges. The closely interacting national initiatives CAMP (Center for Advanced Medical Products) and SWElife-ATMP aim to establish Sweden as one of the international leaders in the ATMP field. Taking into account Sweden’s systems and organizational challenges, these programs nationally coordinate efforts focusing on industry and SME growth, clinical practice, research and education, advanced production, and a flourishing innovation and business environment that in the long term has potential to become a major driving force for the development of a new sector in the Swedish life science industry.